Scientific Publications
[White Paper] Molecular Imaging: Changing the Way We Look at Cancer
Australasian Biotechnology | Vol 33 Number 1 Imagion authored a white paper, published in the April issue of Australasian Biotechnology, discussing current medical imaging technologies,
Imagion presents MagSense® interim study results at breast cancer meeting
Imaging agent aids in resolving nodal status MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of
Imagion to Present Prostate Cancer Research Data at WMIC 2022
https://youtu.be/iH0a08glQYo Imagion to present prostate cancer research data at World Molecular Imaging Congress MagSense® molecular imaging agent shows high specificity and selectivity MELBOURNE — Imagion
Iron Oxide Nanoparticles in Lipid Delivery System May Lead to Better Cancer Treatment
Lipids are frequently used to form drug carrying nanoparticles because of their favorable biocompatibility. However, construction of such drug-carrying lipid nanoparticles often involves multiple steps.
Imagion Biosystems Nanoparticles Used in Viral Therapy Research
Imagion Biosystems Limited is pleased to share news of a recent publication, led by researchers at the Weill Cornell Medical College, which reports use of
2019 World Molecular Imaging Conference Poster
This study is the Company’s first reported results demonstrating that the anti-HER2 nanoparticles used in Imagion’s Magsense™ technology, which provide specific targeting of cancerous cells,
HER2 Nanoparticle Safety and Specificity Data Presented at AACR 2019
Marie Zhang, PhD, Vice President of Research and Clinical Development at Imagion Biosystems, presented the poster “HER2 Functionalized Nanoparticles Are Safe and Specific for in
MagSense® Pre-Clinical Study Presented at 2018 SABCS
On Saturday, December 8, 2018, Marie Zhang, PhD presented the poster “Detection of HER2 Positive Tumor Cells Using Functionalized Iron Oxide Nanoparticles” at the 2018
MagSense® Technology at ASCO 2018 Annual Meeting
The ASCO 2018 Annual Meeting abstract, “Detection and measurement of HER2+ breast cancer cells using tumor-targeted iron oxide nanoparticles and magnetic relaxometry” is now available
MagSense® Pre-Clinical Safety Data from AACR 2018
Pre-clinical data on Imagion Biosystems’ MagSense HER2+ cancer detection platform have shown: specific binding and detection of HER2+ tumor cells in vitro specific detection of
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.